Onconova Therapeutics Company Profile (NASDAQ:ONTX)

About Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics logoOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONTX
  • CUSIP: N/A
  • Web: www.onconova.com
Capitalization:
  • Market Cap: $17.04 million
  • Outstanding Shares: 9,851,000
Average Prices:
  • 50 Day Moving Avg: $1.73
  • 200 Day Moving Avg: $2.16
  • 52 Week Range: $1.50 - $3.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.82
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.36 million
  • Price / Sales: 7.22
  • Book Value: ($0.04) per share
  • Price / Book: -43.25
Profitability:
  • EBIDTA: ($22,150,000.00)
  • Net Margins: -762.13%
  • Return on Equity: -558.97%
  • Return on Assets: -85.62%
Debt:
  • Current Ratio: 1.62%
  • Quick Ratio: 1.62%
Misc:
  • Average Volume: 38,420 shs.
  • Beta: 0.08
  • Short Ratio: 15.94
 

Frequently Asked Questions for Onconova Therapeutics (NASDAQ:ONTX)

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split before market open on Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its earnings results on Monday, August, 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.43. The company earned $0.32 million during the quarter, compared to the consensus estimate of $0.25 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 762.13%. View Onconova Therapeutics' Earnings History.

When will Onconova Therapeutics make its next earnings announcement?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Onconova Therapeutics.

Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2017?

3 brokerages have issued 1-year target prices for Onconova Therapeutics' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Onconova Therapeutics' share price to reach $8.00 in the next year. View Analyst Ratings for Onconova Therapeutics.

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:

  • Michael M. B Hoffman, Chairman of the Board
  • Ramesh Kumar Ph.D., President, Chief Executive Officer, Director
  • Mark Guerin, Chief Financial Officer
  • Steven M. Fruchtman M.D., Senior Vice President - Research and Development, Chief Medical Officer
  • Manoj Maniar Ph.D., Senior Vice President - Product Development
  • Henry S. Bienen Ph.D., Director
  • Jerome E. Groopman M.D., Director
  • Viren Mehta Ph.D., Director
  • E. Premkumar Reddy Ph.D., Director
  • Jack E. Stover CPA, Director

Who owns Onconova Therapeutics stock?

Onconova Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Tyndall Capital Partners L P (10.51%) and Vanguard Group Inc. (0.93%). Company insiders that own Onconova Therapeutics stock include E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Who bought Onconova Therapeutics stock? Who is buying Onconova Therapeutics stock?

Onconova Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Tyndall Capital Partners L P and Vanguard Group Inc.. Company insiders that have bought Onconova Therapeutics stock in the last two years include E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy Onconova Therapeutics stock?

Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of Onconova Therapeutics stock can currently be purchased for approximately $1.73.


MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Onconova Therapeutics (NASDAQ:ONTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (362.43% upside)

Analysts' Ratings History for Onconova Therapeutics (NASDAQ:ONTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/15/2017Maxim GroupSet Price TargetBuy$6.00HighView Rating Details
7/25/2017Dawson JamesReiterated RatingBuyHighView Rating Details
4/27/2017LaidlawInitiated CoverageBuy -> Buy$10.00LowView Rating Details
3/29/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
12/9/2015Piper Jaffray CompaniesReiterated RatingOverweight$60.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Onconova Therapeutics (NASDAQ:ONTX)
Earnings by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Earnings History by Quarter for Onconova Therapeutics (NASDAQ ONTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.73)N/AView Earnings Details
8/14/2017Q2 2017($0.72)($0.29)$0.25 million$0.32 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.96)($1.23)$0.21 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.82)($0.29)$1.60 million$1.70 millionViewN/AView Earnings Details
8/15/2016Q2($1.96)$2.25 millionViewN/AView Earnings Details
5/11/2016Q1($0.19)($0.27)$1.34 million$1.47 millionViewN/AView Earnings Details
3/28/2016Q4($0.27)$0.18$9.60 millionViewN/AView Earnings Details
11/11/2015Q3($0.32)($0.26)$0.11 million$1.62 millionViewN/AView Earnings Details
8/13/2015Q2($0.56)($0.41)$0.11 million$0.12 millionViewN/AView Earnings Details
5/14/2015Q1($0.63)($0.57)$0.11 million$0.11 millionViewN/AView Earnings Details
3/26/2015($0.71)($0.62)$0.11 millionViewN/AView Earnings Details
11/13/2014($0.78)($0.69)$0.11 millionViewN/AView Earnings Details
8/13/2014($0.89)($0.77)$0.56 million$0.13 millionViewN/AView Earnings Details
5/12/2014($0.78)($0.87)$1.32 million$0.45 millionViewN/AView Earnings Details
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details
9/6/2013Q213($5.21)$0.22 million$0.59 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Onconova Therapeutics (NASDAQ:ONTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.72)($0.72)($0.72)
Q3 20171($0.73)($0.73)($0.73)
Q4 20171($0.74)($0.74)($0.74)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Onconova Therapeutics (NASDAQ:ONTX)
Insider Ownership Percentage: 27.30%
Institutional Ownership Percentage: 26.83%
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Institutional Ownership by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/26/2017E Premkumar ReddyDirectorBuy119,048$2.10$250,000.80View SEC Filing  
4/26/2017Mark Patrick GuerinCFOBuy1,429$2.10$3,000.90View SEC Filing  
4/26/2017Ramesh KumarInsiderBuy23,810$2.10$50,001.00View SEC Filing  
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.60View SEC Filing  
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.00View SEC Filing  
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.00View SEC Filing  
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.00View SEC Filing  
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Onconova Therapeutics (NASDAQ:ONTX)
Latest Headlines for Onconova Therapeutics (NASDAQ:ONTX)
Source:
DateHeadline
streetinsider.com logoCellectar Biosciences (CLRB) Reports Strategic Collaboration with Onconova Therapeutics (ONTX) to Develop New ... - StreetInsider.com
www.streetinsider.com - September 22 at 7:31 AM
americanbankingnews.com logoHead-To-Head Survey: Onconova Therapeutics (ONTX) versus Sonoma Pharmaceuticals (SNOA)
www.americanbankingnews.com - September 15 at 10:20 AM
americanbankingnews.com logoChemoCentryx (CCXI) & Onconova Therapeutics (ONTX) Financial Contrast
www.americanbankingnews.com - September 11 at 8:18 PM
finance.yahoo.com logoOnconova Therapeutics to Participate in Two Investor Conferences in September
finance.yahoo.com - September 6 at 7:14 AM
americanbankingnews.com logoOnconova Therapeutics, Inc. (ONTX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - September 2 at 7:32 PM
globenewswire.com logoOnconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 17 at 6:35 AM
finance.yahoo.com logoEdited Transcript of ONTX earnings conference call or presentation 15-Aug-17 1:00pm GMT
finance.yahoo.com - August 17 at 6:35 AM
finance.yahoo.com logoOnconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results
finance.yahoo.com - August 16 at 6:31 AM
americanbankingnews.com logoMaxim Group Analysts Give Onconova Therapeutics, Inc. (ONTX) a $6.00 Price Target
www.americanbankingnews.com - August 15 at 3:10 PM
americanbankingnews.com logoOnconova Therapeutics, Inc. (ONTX) Announces Earnings Results, Beats Expectations By $0.43 EPS
www.americanbankingnews.com - August 15 at 1:10 PM
americanbankingnews.com logoOnconova Therapeutics Inc (NASDAQ:ONTX) to Release Earnings on Monday
www.americanbankingnews.com - August 11 at 8:32 PM
finance.yahoo.com logoOnconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 6:06 AM
americanbankingnews.com logoOnconova Therapeutics, Inc. (NASDAQ:ONTX) Given "Buy" Rating at Dawson James
www.americanbankingnews.com - July 30 at 10:36 AM
americanbankingnews.com logoEquities Analysts Set Expectations for Onconova Therapeutics, Inc.'s Q2 2017 Earnings (NASDAQ:ONTX)
www.americanbankingnews.com - July 28 at 9:49 AM
globenewswire.com logoOnconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating ... - GlobeNewswire (press release)
globenewswire.com - July 26 at 6:07 AM
finance.yahoo.com logoOnconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”
finance.yahoo.com - July 26 at 6:07 AM
finance.yahoo.com logoOnconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”
finance.yahoo.com - July 26 at 6:07 AM
americanbankingnews.com logoZacks: Onconova Therapeutics, Inc. (NASDAQ:ONTX) Given $5.50 Consensus Price Target by Brokerages
www.americanbankingnews.com - July 12 at 12:55 PM
streetinsider.com logoOnconova Therapeutics (ONTX) Presents Rigosertib Data at EHA
www.streetinsider.com - June 27 at 7:08 PM
americanbankingnews.com logo Onconova Therapeutics, Inc. (ONTX) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 27 at 9:06 AM
streetinsider.com logoOnconova Therapeutics (ONTX) Presents Rigosertib Data at EHA - StreetInsider.com
www.streetinsider.com - June 27 at 6:56 AM
finance.yahoo.com logoOnconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid
finance.yahoo.com - June 27 at 6:56 AM
finance.yahoo.com logoOnconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 8:00 PM
feeds.benzinga.com logoOnconova Therapeutics to Present at the BIO International Convention
feeds.benzinga.com - June 13 at 8:52 AM
americanbankingnews.com logoZacks: Onconova Therapeutics, Inc. (ONTX) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 12 at 8:38 AM
americanbankingnews.com logoOnconova Therapeutics Inc (ONTX) Given a $6.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - June 7 at 4:50 PM
marketwatch.com logoUPDATE: Onconova Therapeutics stock surges 7% on positive mid-stage clinical trial results - MarketWatch
www.marketwatch.com - June 6 at 8:28 AM
streetinsider.com logoOnconova Therapeutics (ONTX) Reports Positive Phase 2 Data in Rigosertib Treated Patients with Second-line ... - StreetInsider.com
www.streetinsider.com - June 6 at 8:28 AM
finance.yahoo.com logoOnconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - June 5 at 7:39 PM
finance.yahoo.com logoUPDATE: Onconova Therapeutics stock surges 7% on positive mid-stage clinical trial results
finance.yahoo.com - June 5 at 7:39 PM
americanbankingnews.com logoZacks: Onconova Therapeutics Inc (ONTX) Given Average Recommendation of "" by Analysts
www.americanbankingnews.com - May 24 at 4:10 PM
finance.yahoo.com logoOnconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association
finance.yahoo.com - May 22 at 9:45 AM
finance.yahoo.com logoOnconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 19 at 11:49 AM
finance.yahoo.com logoEdited Transcript of ONTX earnings conference call or presentation 15-May-17 1:00pm GMT
finance.yahoo.com - May 16 at 6:46 PM
americanbankingnews.com logoOnconova Therapeutics Inc (ONTX) Releases Quarterly Earnings Results, Misses Expectations By $0.27 EPS
www.americanbankingnews.com - May 16 at 6:14 PM
americanbankingnews.com logoOnconova Therapeutics Inc (ONTX) PT Set at $6.00 by Maxim Group
www.americanbankingnews.com - May 15 at 3:14 PM
finance.yahoo.com logoInvestor Network: Onconova Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 9:59 AM
finance.yahoo.com logoOnconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 9:59 AM
nasdaq.com logoOnconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - May 5 at 7:19 PM
americanbankingnews.com logo Onconova Therapeutics Inc (ONTX) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 5 at 2:28 PM
finance.yahoo.com logoOnconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 7:13 PM
americanbankingnews.com logoOnconova Therapeutics (ONTX) Given Daily Media Sentiment Score of 0.17
www.americanbankingnews.com - May 4 at 11:17 AM
finance.yahoo.com logoOnconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes - Yahoo Finance
finance.yahoo.com - May 1 at 12:04 PM
finance.yahoo.com logoOnconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes
finance.yahoo.com - May 1 at 12:04 PM
bizjournals.com logoBucks County biopharm firm closes $5.2M stock sale
www.bizjournals.com - April 29 at 7:28 PM
americanbankingnews.com logoRamesh Kumar Acquires 23,810 Shares of Onconova Therapeutics Inc (ONTX) Stock
www.americanbankingnews.com - April 28 at 7:28 PM
americanbankingnews.com logoE Premkumar Reddy Purchases 119,048 Shares of Onconova Therapeutics Inc (ONTX) Stock
www.americanbankingnews.com - April 28 at 7:27 PM
americanbankingnews.com logoLaidlaw Initiates Coverage on Onconova Therapeutics Inc (ONTX)
www.americanbankingnews.com - April 27 at 10:12 PM
globenewswire.com logoOnconova Therapeutics Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - April 27 at 7:30 PM
americanbankingnews.com logoOnconova Therapeutics (ONTX) Earning Somewhat Negative Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 27 at 5:04 PM

Social

Chart

Onconova Therapeutics (ONTX) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff